Science for Life Laboratory, Solna, Sweden; The Royal Institute of Technology, Division of Systems Biology, Department of Protein Science, School of Chemistry, Biotechnology and Health, Stockholm, Sweden
Dominic Foley
Waters Corporation, Milford, United Kingdom
Thomas McDonald
Waters Corporation, Milford, United Kingdom
Johannes PC Vissers
Waters Corporation, Milford, United Kingdom
Rebecca Pattison
Waters Corporation, Milford, United Kingdom
Samantha Ferries
Waters Corporation, Milford, United Kingdom
Sigurd Hermansson
Waters Corporation, Milford, United Kingdom
Ingvar Betner
Waters Corporation, Milford, United Kingdom
Mathias Uhlén
Science for Life Laboratory, Solna, Sweden; The Royal Institute of Technology, Division of Systems Biology, Department of Protein Science, School of Chemistry, Biotechnology and Health, Stockholm, Sweden
Morteza Razavi
SISCAPA Assay Technologies, Inc, Victoria, Canada
Richard Yip
SISCAPA Assay Technologies, Inc, Victoria, Canada
Matthew E Pope
SISCAPA Assay Technologies, Inc, Victoria, Canada
Terry W Pearson
SISCAPA Assay Technologies, Inc, Victoria, Canada
Leigh N Andersson
SISCAPA Assay Technologies, Inc, Victoria, Canada
Amy Bartlett
Waters Corporation, Milford, United Kingdom
Lisa Calton
Waters Corporation, Milford, United Kingdom
Jessica J Alm
Karolinska Institutet, Department of Microbiology, Tumor and Cell Biology & National Pandemic Center, Karolinska Institutet, Solna, Sweden
Lars Engstrand
Microbiology, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Sweden
Science for Life Laboratory, Solna, Sweden; The Royal Institute of Technology, Division of Systems Biology, Department of Protein Science, School of Chemistry, Biotechnology and Health, Stockholm, Sweden
Reliable, robust, large-scale molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for monitoring the ongoing coronavirus disease 2019 (COVID-19) pandemic. We have developed a scalable analytical approach to detect viral proteins based on peptide immuno-affinity enrichment combined with liquid chromatography-mass spectrometry (LC-MS). This is a multiplexed strategy, based on targeted proteomics analysis and read-out by LC-MS, capable of precisely quantifying and confirming the presence of SARS-CoV-2 in phosphate-buffered saline (PBS) swab media from combined throat/nasopharynx/saliva samples. The results reveal that the levels of SARS-CoV-2 measured by LC-MS correlate well with their correspondingreal-time polymerase chain reaction (RT-PCR) read-out (r = 0.79). The analytical workflow shows similar turnaround times as regular RT-PCR instrumentation with a quantitative read-out of viral proteins corresponding to cycle thresholds (Ct) equivalents ranging from 21 to 34. Using RT-PCR as a reference, we demonstrate that the LC-MS-based method has 100% negative percent agreement (estimated specificity) and 95% positive percent agreement (estimated sensitivity) when analyzing clinical samples collected from asymptomatic individuals with a Ct within the limit of detection of the mass spectrometer (Ct ≤ 30). These results suggest that a scalable analytical method based on LC-MS has a place in future pandemic preparedness centers to complement current virus detection technologies.